Patent · US Active

Inhibitors of the menin-MLL interaction

US11479557B2 · kind B2 · utility

2Cited by

2References

23Claims

0Family size

Assignee

Vitae Pharmaceuticals, LLC · US

Inventors

Salvacion Cacatian · Conshohocken, US
David A. Claremon · Audubon, US
Lawrence Wayne Dillard · Yardley, US
Chengguo Dong · Staten Island, US
Yi Fan · Lawrence, US
Lanqi Jia · Horsham, US
Stephen D. Lotesta · Burlington, US
Andrew Marcus · Media, US
Angel Morales-Ramos · Blue Bell, US
Suresh B. Singh · Kendall Park, US
Shankar Venkatraman · Lansdale, US
Jing Yuan · Lansdale, US
Yajun Zheng · Hockessin, US
Linghang Zhuang · Doylestown, US
Stephan D. Parent · West Lafayette, US
Travis L. Houston · Lafayette, US

Key dates

Filing date	Apr 1, 2020
Grant date	Oct 25, 2022
Priority date	—
Expiry date	Apr 1, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.